Mellanstungvikt

Mellanstungvikt is a neurological condition that manifests as a weakness or atrophy of the tongue muscles, primarily affecting the mid‑line portion of the tongue. It is usually caused by lesions or damage to the hypoglossal nerve (cranial nerve XII), or by systemic neuromuscular disorders such as motor neuron disease or myasthenia gravis. In some cases, mild strokes or chronic inflammatory diseases such as sarcoidosis can produce a similar pattern of tongue weakness.

The hallmark clinical sign is an inability to protrude or pull the tongue toward the midline, leading to a Pisa‑like posture of the tongue or a deviated tongue on protrusion. Patients may experience difficulties with speech, chewing, and swallowing, and they often report a sensation of “tightness” in the tongue. On examination, the tongue may show atrophy of the central musculature and reduced sensation to touch or pain in the affected area. In severe cases, the tongue may not be able to remain in contact with the palate during phonation, producing a nasal tone to speech.

Diagnosis is obtained through a combination of a detailed neurological history, a focused oral examination, and imaging studies such as MRI or CT scans to identify lesions along the hypoglossal tract. Electrophysiological testing of the hypoglossal nerve may also be employed to assess conduction status. Treatment depends on the underlying cause. For example, if the cause is an inflammatory process, immunosuppressive therapy may be indicated; in the case of a demyelinating lesion, corticosteroids are often used. Physical therapy and speech therapy are recommended to improve tongue strength and articulation.

Prognosis varies widely – if the root cause is reversible, such as in inflammatory or autoimmune conditions, improvements can be dramatic. However, in chronic neurodegenerative disorders, deficits tend to accumulate, and management focuses on maintaining speech and swallowing function. Research into targeted neuromodulation and regenerative therapies is ongoing, with some early-stage trials exploring the use of trans‑cranial magnetic stimulation and stem‑cell approaches for restoring hypoglossal function.